Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASi-HF Reduced
NCT06935370Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in chronic heart failure (CHF) comparing vicadrostat/empagliflozin treatment group with Placebo to vicadrostat/empagliflozin treatment group (2 arms). Primary endpoint: Time to first event of Cardiovascular death, Hospitalisation for heart failure, or Urgent heart failure visit up to 43 months. Started May 2025; status: recruiting.
02
Drugs
vicadrostat
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT06935370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06935370.